EUCTR2015-002378-19-NL进行中（未招募）1 期
International, multi-center, randomized, double-blind, placebo-controlled phase III study assessing in parallel groups the efficacy and safety of 2 doses of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A treated 15 months - PLEO-CMT
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- PHARNEXT SA
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female, aged from 16 to 65 years;
- •2. Patient with a proven genetic diagnosis of CMT1A;
- •3. Mild-to-moderate severity assessed by CMTNS-v2 with a score >2 and =18;
- •4. Muscle weakness in at least foot dorsiflexion;
- •5. Motor nerve conduction of the ulnar nerve of at least 15m/sec;
- •6. Providing signed written informed consent to participate in the study and willing and able to comply with all study procedures and scheduled visits.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 30
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 270
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Any other associated cause of peripheral neuropathy such as diabetes;
- •2. Patients with another significant neurological disease or a concomitant major systemic disease;
- •3. Clinically significant history of unstable medical illness since the last 30 days (unstable angina, cancer…) that may jeopardize the participation in the study;
- •4. Significant hematologic disease, hepatitis or liver failure, renal failure;
- •5. Limb surgery within six months before randomization or planned before trial completion;
- •6. Clinically significant abnormalities on the pre-study laboratory evaluation, physical evaluation, electrocardiogram (ECG);
- •7. Elevated ASAT/ALAT (> 3 x ULN) and elevated serum creatinine levels (> 1.25 x ULN);
- •8. History of recent alcohol or drug abuse or non-adherence with treatment or other experimental protocols;
- •9. Patients using unauthorized concomitant treatments including but not limited to baclofen, naltrexone, sorbitol (pharmaceutical form), opioids, levothyroxin and potentially neurotoxic drugs such as amiodarone, chloroquine, cancer drugs susceptible to induce a peripheral neuropathy; (list provided in appendix 1). Patients who can/agree to stop these medications 4 weeks before randomization and during the whole study duration can be included;
- •10. Female of childbearing potential (apart of patients using adequate contraceptive measures), pregnant or breast feeding;
- •11. Known hypersensitivity to any of the individual components of PXT3003;
- •12. Porphyria as it is a contra indication to baclofen, and it may also induce neuropathy;
- •13. Suspected inability to complete the study follow-up (foreign workers, transient visitors, tourists or any others for whom follow-up evaluation is not assured);
- •14. Limited mental capacity or psychiatric disease rendering the subject unable to provide written informed consent or comply with evaluation procedures;
- •15. Patients who have participated in another trial of investigational drug(s) within the past 30 days;
- •16. If a patient from the same family, living in the same household, has already been included in this study, it will not be possible to include another patient from the same family to avoid mixing of therapeutic units; therefore there would be a risk of inversion of the blind treatments which could jeopardize the interpretation of study results.
研究者
相似试验
进行中（未招募）
1 期
International, multi-center, randomized, double-blind, placebo-controlled phase III study assessing in parallel groups the efficacy and safety of 2 doses of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A treated 15 monthsCharcot-Marie-Tooth Disease - Type 1AMedDRA version: 20.0 Level: LLT Classification code 10008414 Term: Charcot-Marie-Tooth disease System Organ Class: 100000004850EUCTR2015-002378-19-GBPHARNEXT323
进行中（未招募）
1 期
International, multi-center, randomized, double-blind, placebo-controlled phase III study assessing in parallel groups the efficacy and safety of 2 doses of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A treated 15 monthsEUCTR2015-002378-19-DEPHARNEXT300
已完成
3 期
International, multi-center, randomized, double-blind, placebo-controlled phase III study assessing in parallel groups the efficacy and safety of 2 doses of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A treated 15 monthsHMSN hereditary motor and sensory neuropathie1002929910034606NL-OMON46863Pharnext20
进行中（未招募）
1 期
International, multi-center, randomized, double-blind, placebo-controlled phase III study assessing in parallel groups the efficacy and safety of 2 doses of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A treated 15 monthsCharcot-Marie-Tooth Disease - Type 1AMedDRA version: 18.1 Level: LLT Classification code 10008414 Term: Charcot-Marie-Tooth disease System Organ Class: 100000004850EUCTR2015-002378-19-ESPHARNEXT323
进行中（未招募）
1 期
International, multi-center, randomized, double-blind, placebo-controlled phase III study assessing in parallel groups the efficacy and safety of 2 doses of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A treated 15 monthsCharcot-Marie-Tooth Disease - Type 1AMedDRA version: 18.0 Level: LLT Classification code 10008414 Term: Charcot-Marie-Tooth disease System Organ Class: 100000004850EUCTR2015-002378-19-FRPHARNEXT323